CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Uncover the best ways to sell your crafts for money and maximize your profits. Let your creativity pay off in no time!
19,146 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A government-contract windfall sparked a sharp rally in Viasat stock. This article breaks down the news, the technolo...
A small monthly pension moved a 68-year-old retiree into a government tax bracket she didn’t anticipate, underscoring...
Healthcare megacaps Pfizer and Johnson & Johnson continue to deliver quarterly dividends that can generate reliable i...
Investors dig into a mixed session as Amazon leads gains on Prime Day momentum and AI shopping activity. This guide b...
A domestic uranium producer is expanding beyond ore to processing key minerals. This article breaks down the strategy...
As volatility stays elevated, a hedge against rising option premiums is gaining attention. The 8%-yield S&P 500 Premi...
AI data centers are sparking a sweeping power expansion in the U.S. Three utility ETFs offer distinct routes to ride ...
A growing cohort of dentists is turning to cash-balance plans to fund retirement beyond 401(k) limits, giving practic...
Two leading cybersecurity ETFs are signaling different bets on digital defense. CIBR emphasizes software platforms, w...
A sudden political pivot put South Carolina in the spotlight as former President Trump floated Darline Graham Nordone...
As tesla heads into july, the market faces a tug-of-war: robust quarterly deliveries versus pressure on margins and a...